Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease.

[1]  Masayuki Hata,et al.  Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations. , 2007, Journal of medicinal chemistry.

[2]  Heinrich Sticht,et al.  Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations , 2007, Journal of molecular modeling.

[3]  P. Pascutti,et al.  Molecular dynamics simulations applied to the study of subtypes of HIV-1 protease common to Brazil, Africa, and Asia , 2007, Cell Biochemistry and Biophysics.

[4]  D. Billingham.  Does the world need another AIDS authority? , 2006, The Lancet.

[5]  Jindrich Hasek,et al.  HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site. , 2006, Journal of medicinal chemistry.

[6]  Deenan Pillay,et al.  Update of the drug resistance mutations in HIV-1: Fall 2006. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[7]  Masayuki Hata,et al.  Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M. , 2006, Journal of the American Chemical Society.

[8]  Maureen M Goodenow,et al.  Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir. , 2006, Biochemistry.

[9]  Anne-Mieke Vandamme,et al.  Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G , 2005, AIDS.

[10]  Lynn Morris,et al.  Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration , 2005, PLoS medicine.

[11]  Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases. , 2005, The journal of physical chemistry. B.

[12]  Marcelo A. Soares,et al.  Impact of Nelfinavir Resistance Mutations on In Vitro Phenotype, Fitness, and Replication Capacity of Human Immunodeficiency Virus Type 1 with Subtype B and C Proteases , 2004, Antimicrobial Agents and Chemotherapy.

[13]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[14]  Dan Engelhard,et al.  Mutation D30N Is Not Preferentially Selected by Human Immunodeficiency Virus Type 1 Subtype C in the Development of Resistance to Nelfinavir , 2004, Antimicrobial Agents and Chemotherapy.

[15]  D. Case,et al.  Exploring protein native states and large‐scale conformational changes with a modified generalized born model , 2004, Proteins.

[16]  J. Nkengasong,et al.  HIV antiretroviral drug resistance in Africa. , 2004, AIDS reviews.

[17]  Maureen M Goodenow,et al.  Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. , 2003, Biochemistry.

[18]  Irene T. Weber,et al.  Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro , 2003, Antimicrobial Agents and Chemotherapy.

[19]  Wei Zhang,et al.  A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..

[20]  Kaneo Yamada,et al.  Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. , 2003, Journal of acquired immune deficiency syndromes.

[21]  D. Katzenstein,et al.  Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. , 2003, AIDS reviews.

[22]  Ursula Rothlisberger,et al.  Drug resistance in HIV‐1 protease: Flexibility‐assisted mechanism of compensatory mutations , 2002, Protein science : a publication of the Protein Society.

[23]  Brendan Larder,et al.  Interference between D30N and L90M in Selection and Development of Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1 , 2002, Antimicrobial Agents and Chemotherapy.

[24]  M Karplus,et al.  Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. , 2002, Journal of molecular biology.

[25]  T. Hahn.  International tables for crystallography , 2002 .

[26]  Zehava Grossman,et al.  Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B , 2001, AIDS.

[27]  D. Pillay,et al.  Resistance-Associated Mutations in the Human Immunodeficiency Virus Type 1 Subtype C Protease Gene from Treated and Untreated Patients in the United Kingdom , 2001, Journal of Clinical Microbiology.

[28]  P A Kollman,et al.  Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model. , 2000, Journal of molecular biology.

[29]  Martine Peeters,et al.  Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients , 2000, Journal of Clinical Microbiology.

[30]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[31]  Brendan A. Larder,et al.  Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples , 2000, AIDS.

[32]  David A. Stock,et al.  BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents , 2000, Antimicrobial Agents and Chemotherapy.

[33]  D J Hu,et al.  Protease sequences from HIV-1 group M subtypes A–H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide , 2000, AIDS.

[34]  P. Kollman,et al.  Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .

[35]  Masayuki Hata,et al.  Hydrolysis Mechanism of the Phenylalanine−Proline Peptide Bond Specific to HIV-1 Protease: Investigation by the ab Initio Molecular Orbital Method , 1999 .

[36]  Dale J. Kempf,et al.  In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor , 1998, Journal of Virology.

[37]  H. Edelsbrunner,et al.  Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design , 1998, Protein science : a publication of the Protein Society.

[38]  P. Kollman,et al.  Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate−DNA Helices , 1998 .

[39]  N. Chirgadze,et al.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. , 1997, Journal of medicinal chemistry.

[40]  Remco,et al.  pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D , 1997, Journal of virology.

[41]  D. Ho,et al.  Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease , 1996, Antimicrobial agents and chemotherapy.

[42]  S. Pazhanisamy,et al.  Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. , 1995, The Journal of infectious diseases.

[43]  S. Vasavanonda,et al.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Darke,et al.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[46]  J S Mills,et al.  Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. , 1991, Antiviral research.

[47]  M. Hatada,et al.  Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.

[48]  I B Duncan,et al.  Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.

[49]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[50]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[51]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .